Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer
Oral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and metalloprotease 9 (ADAM9) in oral cancer progression and outcomes. This study investigated ADAM9 protein expression in 353 oral cancer tissue specimens...
Saved in:
| Published in | Oral diseases |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Denmark
16.06.2025
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1354-523X 1601-0825 1601-0825 |
| DOI | 10.1111/odi.15383 |
Cover
Loading…
| Abstract | Oral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and metalloprotease 9 (ADAM9) in oral cancer progression and outcomes.
This study investigated ADAM9 protein expression in 353 oral cancer tissue specimens through immunohistochemical (IHC) analysis.
The analysis revealed that, among the 353 patients, 21 (6%) exhibited low ADAM9 expression, while the remaining 332 patients (94%) showed high ADAM9 expression, which correlated with advanced T status, poor overall survival, and unfavorable prognosis. Kaplan-Meier analysis confirmed that higher ADAM9 expression predicted significantly worse survival. Univariate and multivariate analyses identified ADAM9, histological grade, and AJCC stage as independent prognostic factors. Functionally, ADAM9 silencing in SAS and OC2 cells inhibited invasion and migration, downregulating matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 14 (MMP14). siRNA-mediated ADAM9 knockdown also reduced cell viability and migration, as confirmed by cell counting kit-8 and transwell assays. The Cancer Genome Atlas (TCGA) analysis further revealed a positive correlation between ADAM9 mRNA levels and matrix metalloproteinase 2 (MMP2) or MMP14 expression in oral cancer patients.
This study identifies ADAM9 as a key driver of oral cancer in a Taiwanese cohort and highlights its diagnostic and therapeutic potential. |
|---|---|
| AbstractList | Oral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and metalloprotease 9 (ADAM9) in oral cancer progression and outcomes.
This study investigated ADAM9 protein expression in 353 oral cancer tissue specimens through immunohistochemical (IHC) analysis.
The analysis revealed that, among the 353 patients, 21 (6%) exhibited low ADAM9 expression, while the remaining 332 patients (94%) showed high ADAM9 expression, which correlated with advanced T status, poor overall survival, and unfavorable prognosis. Kaplan-Meier analysis confirmed that higher ADAM9 expression predicted significantly worse survival. Univariate and multivariate analyses identified ADAM9, histological grade, and AJCC stage as independent prognostic factors. Functionally, ADAM9 silencing in SAS and OC2 cells inhibited invasion and migration, downregulating matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 14 (MMP14). siRNA-mediated ADAM9 knockdown also reduced cell viability and migration, as confirmed by cell counting kit-8 and transwell assays. The Cancer Genome Atlas (TCGA) analysis further revealed a positive correlation between ADAM9 mRNA levels and matrix metalloproteinase 2 (MMP2) or MMP14 expression in oral cancer patients.
This study identifies ADAM9 as a key driver of oral cancer in a Taiwanese cohort and highlights its diagnostic and therapeutic potential. Oral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and metalloprotease 9 (ADAM9) in oral cancer progression and outcomes.BACKGROUNDOral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and metalloprotease 9 (ADAM9) in oral cancer progression and outcomes.This study investigated ADAM9 protein expression in 353 oral cancer tissue specimens through immunohistochemical (IHC) analysis.METHODSThis study investigated ADAM9 protein expression in 353 oral cancer tissue specimens through immunohistochemical (IHC) analysis.The analysis revealed that, among the 353 patients, 21 (6%) exhibited low ADAM9 expression, while the remaining 332 patients (94%) showed high ADAM9 expression, which correlated with advanced T status, poor overall survival, and unfavorable prognosis. Kaplan-Meier analysis confirmed that higher ADAM9 expression predicted significantly worse survival. Univariate and multivariate analyses identified ADAM9, histological grade, and AJCC stage as independent prognostic factors. Functionally, ADAM9 silencing in SAS and OC2 cells inhibited invasion and migration, downregulating matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 14 (MMP14). siRNA-mediated ADAM9 knockdown also reduced cell viability and migration, as confirmed by cell counting kit-8 and transwell assays. The Cancer Genome Atlas (TCGA) analysis further revealed a positive correlation between ADAM9 mRNA levels and matrix metalloproteinase 2 (MMP2) or MMP14 expression in oral cancer patients.RESULTSThe analysis revealed that, among the 353 patients, 21 (6%) exhibited low ADAM9 expression, while the remaining 332 patients (94%) showed high ADAM9 expression, which correlated with advanced T status, poor overall survival, and unfavorable prognosis. Kaplan-Meier analysis confirmed that higher ADAM9 expression predicted significantly worse survival. Univariate and multivariate analyses identified ADAM9, histological grade, and AJCC stage as independent prognostic factors. Functionally, ADAM9 silencing in SAS and OC2 cells inhibited invasion and migration, downregulating matrix metalloproteinase 9 (MMP9) and matrix metalloproteinase 14 (MMP14). siRNA-mediated ADAM9 knockdown also reduced cell viability and migration, as confirmed by cell counting kit-8 and transwell assays. The Cancer Genome Atlas (TCGA) analysis further revealed a positive correlation between ADAM9 mRNA levels and matrix metalloproteinase 2 (MMP2) or MMP14 expression in oral cancer patients.This study identifies ADAM9 as a key driver of oral cancer in a Taiwanese cohort and highlights its diagnostic and therapeutic potential.CONCLUSIONSThis study identifies ADAM9 as a key driver of oral cancer in a Taiwanese cohort and highlights its diagnostic and therapeutic potential. |
| Author | Chuang, Show‐Mei Tsai, Ming‐Heng Lin, Shu‐Hui Shih, Pei‐Chen Tsai, Yun‐Jung Lu, Jeng‐Wei Tu, Wan‐Jung |
| Author_xml | – sequence: 1 givenname: Jeng‐Wei orcidid: 0000-0003-2128-2046 surname: Lu fullname: Lu, Jeng‐Wei organization: Department of Bioscience and Biotechnology National Taiwan Ocean University Keelung Taiwan, Biotech Research and Innovation Centre University of Copenhagen Copenhagen Denmark, The Finsen Laboratory, Rigshospitalet/National University Hospital, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark – sequence: 2 givenname: Pei‐Chen surname: Shih fullname: Shih, Pei‐Chen organization: Institute of Biomedical Sciences National Chung Hsing University Taichung Taiwan – sequence: 3 givenname: Show‐Mei surname: Chuang fullname: Chuang, Show‐Mei organization: Department of Post‐Baccalaureate Medicine National Chung Hsing University Taichung Taiwan, Graduate Institute of Clinical Nursing National Chung Hsing University Taichung Taiwan, Graduate Institute of Clinical Medicine National Chung Hsing University Taichung Taiwan, Department of law National Chung Hsing University Taichung Taiwan, Department of Surgical Pathology Yuanlin Christian Hospital Changhua Taiwan – sequence: 4 givenname: Wan‐Jung surname: Tu fullname: Tu, Wan‐Jung organization: Department of Life Sciences National Chung Hsing University Taichung Taiwan – sequence: 5 givenname: Ming‐Heng surname: Tsai fullname: Tsai, Ming‐Heng organization: Translational Pathology Core Laboratory Changhua Christian Hospital Changhua Taiwan – sequence: 6 givenname: Yun‐Jung surname: Tsai fullname: Tsai, Yun‐Jung organization: Department of Surgical Pathology Changhua Christian Hospital Changhua Taiwan – sequence: 7 givenname: Shu‐Hui surname: Lin fullname: Lin, Shu‐Hui organization: Department of Surgical Pathology Changhua Christian Hospital Changhua Taiwan, Department of Medical Laboratory Science and Biotechnology Central Taiwan University of Science and Technology Taichung Taiwan, Department of Post‐Baccalaureate Medicine, College of Medicine National Chung Hsing University Taichung Taiwan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40523161$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kMtOwzAQRS1URB-w4AeQl7BI8SNO4mUJ5SEVlQUgdpHrjJEhtYudLvh7DC3MZkajM6N77xgNnHeA0CklU5rq0rd2SgWv-AEa0YLQjFRMDNLMRZ4Jxl-HaBzjOyG0lJwdoWFO0pYWdITmdWed1arDL6qzreqtd9gbPLuePUisIlb4Mfg352NvNb6yfq3CBwRsHV6GdFUrpyEco0Ojuggn-z5Bzzfzp_ouWyxv7-vZItMsL_tMCliJSsi2FYZIKIFqAqVkVHGhpDZtJVecFxRMmUNhpBGKGymUMTyvWsP4BJ3v_m6C_9xC7Ju1jRq6Tjnw29hwRpPBPC_LhJ7t0e1qDW2zCTZJ_2r-rCfgYgfo4GMMYP4RSpqfWJsUa_MbK_8G6t5oFQ |
| Cites_doi | 10.3892/ol.2018.8999 10.3892/ol.2013.1209 10.1016/j.mam.2008.08.001 10.1016/j.ygyno.2009.05.005 10.1111/jpi.12760 10.3390/medicina57020164 10.4103/1117-1936.165361 10.1111/eos.12775 10.1093/jjco/hyq030 10.1093/carcin/bgaa062 10.1186/s13046‐019‐1238‐4 10.1158/0008‐5472.CAN‐13‐2995 10.18632/oncotarget.20079 10.1016/j.oraloncology.2011.09.013 10.1038/srep16426 10.1615/CritRevTherDrugCarrierSyst.2016016272 10.1158/0008‐5472.CAN‐04‐4449 10.1186/1471‐2407‐8‐179 10.3390/cells5020016 10.3892/ol.2017.7284 10.1016/s1368‐8375(00)00021‐x 10.1007/s12032‐025‐02645‐0 10.3390/ijms17091276 10.1038/s41368‐023‐00249‐w 10.1016/j.eururo.2007.11.034 10.1158/1078‐0432.CCR‐14‐1740 10.1371/journal.pone.0054705 10.1016/j.oraloncology.2008.06.002 10.3892/or.2016.5259 10.1159/000324314 10.1111/odi.15076 10.1007/s12672‐024‐01422‐1 10.3389/fmed.2020.00214 10.7150/ijms.74751 10.4049/jimmunol.1303370 10.1158/0008‐5472.CAN‐16‐2609 10.1155/2017/5815493 10.1371/journal.pone.0021816 10.1158/1078‐0432.CCR‐09‐2525 10.1111/j.1834‐7819.2011.01349.x 10.1158/1535‐7163.MCT‐13‐1001 10.7150/thno.18551 10.3390/diagnostics10020122 10.2147/CMAR.S277096 10.1186/s13046‐019‐1455‐x 10.1016/j.canlet.2018.02.010 10.1002/ijc.23974 10.1016/j.oraloncology.2020.104915 10.1074/jbc.M111.321190 10.1158/0008‐5472.CAN‐09‐4231 10.3322/caac.21492 10.3109/08941939.2012.728682 10.1111/jpi.12370 10.1016/j.oraloncology.2020.104798 10.1007/s11010‐009‐0217‐z 10.1016/j.oraloncology.2008.05.017 10.1016/j.oraloncology.2017.12.005 10.1074/jbc.M701658200 |
| ContentType | Journal Article |
| Copyright | 2025 John Wiley & Sons Ltd. |
| Copyright_xml | – notice: 2025 John Wiley & Sons Ltd. |
| DBID | AAYXX CITATION NPM 7X8 |
| DOI | 10.1111/odi.15383 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Dentistry |
| EISSN | 1601-0825 |
| ExternalDocumentID | 40523161 10_1111_odi_15383 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: National Chung-Hsing University – fundername: Changhua Christian Hospital |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 123 1OB 1OC 29N 33P 34H 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5HH 5LA 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AAWTL AAXRX AAYCA AAYXX AAZKR ABCQN ABCUV ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AHMBA AIACR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CITATION CS3 CWXXS D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM EBS F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HGLYW HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI UB1 W8V W99 WBKPD WBNRW WIH WIJ WIK WOHZO WPGGZ WQJ WXI WXSBR XG1 YFH ZZTAW ~IA ~WT NPM 7X8 |
| ID | FETCH-LOGICAL-c247t-95eb5859dd5f09e7e1c0e7921a35a9cfd89b3361ef74e6f9f5a3f95aff348df23 |
| ISSN | 1354-523X 1601-0825 |
| IngestDate | Fri Jul 11 17:04:17 EDT 2025 Sat Jul 12 03:28:32 EDT 2025 Wed Aug 13 23:48:03 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | overall survival ADAM9 immunohistochemistry prognosis oral cancer |
| Language | English |
| License | 2025 John Wiley & Sons Ltd. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c247t-95eb5859dd5f09e7e1c0e7921a35a9cfd89b3361ef74e6f9f5a3f95aff348df23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2128-2046 |
| PMID | 40523161 |
| PQID | 3219324477 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3219324477 pubmed_primary_40523161 crossref_primary_10_1111_odi_15383 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-16 |
| PublicationDateYYYYMMDD | 2025-06-16 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | Denmark |
| PublicationPlace_xml | – name: Denmark |
| PublicationTitle | Oral diseases |
| PublicationTitleAlternate | Oral Dis |
| PublicationYear | 2025 |
| References | Kao S. Y. (e_1_2_11_19_1) 2015; 18 e_1_2_11_32_1 e_1_2_11_55_1 e_1_2_11_30_1 e_1_2_11_57_1 e_1_2_11_36_1 e_1_2_11_51_1 e_1_2_11_13_1 e_1_2_11_53_1 e_1_2_11_11_1 Rosebush M. S. (e_1_2_11_34_1) 2012; 94 e_1_2_11_6_1 e_1_2_11_27_1 e_1_2_11_4_1 e_1_2_11_48_1 e_1_2_11_2_1 Lin Y. S. (e_1_2_11_29_1) 2020; 10 e_1_2_11_60_1 Le T. T. (e_1_2_11_23_1) 2022; 12 e_1_2_11_20_1 e_1_2_11_45_1 e_1_2_11_47_1 e_1_2_11_24_1 e_1_2_11_41_1 e_1_2_11_62_1 e_1_2_11_8_1 e_1_2_11_22_1 e_1_2_11_43_1 e_1_2_11_17_1 e_1_2_11_15_1 e_1_2_11_59_1 e_1_2_11_38_1 e_1_2_11_50_1 e_1_2_11_10_1 e_1_2_11_31_1 e_1_2_11_56_1 e_1_2_11_58_1 e_1_2_11_14_1 e_1_2_11_35_1 e_1_2_11_52_1 e_1_2_11_12_1 e_1_2_11_33_1 e_1_2_11_54_1 e_1_2_11_7_1 e_1_2_11_28_1 e_1_2_11_5_1 e_1_2_11_26_1 e_1_2_11_3_1 e_1_2_11_49_1 e_1_2_11_61_1 e_1_2_11_21_1 e_1_2_11_44_1 e_1_2_11_46_1 e_1_2_11_25_1 e_1_2_11_40_1 e_1_2_11_63_1 e_1_2_11_9_1 e_1_2_11_42_1 e_1_2_11_18_1 e_1_2_11_16_1 e_1_2_11_37_1 e_1_2_11_39_1 |
| References_xml | – ident: e_1_2_11_18_1 doi: 10.3892/ol.2018.8999 – ident: e_1_2_11_59_1 doi: 10.3892/ol.2013.1209 – ident: e_1_2_11_10_1 doi: 10.1016/j.mam.2008.08.001 – ident: e_1_2_11_63_1 doi: 10.1016/j.ygyno.2009.05.005 – ident: e_1_2_11_45_1 doi: 10.1111/jpi.12760 – ident: e_1_2_11_31_1 doi: 10.3390/medicina57020164 – ident: e_1_2_11_2_1 doi: 10.4103/1117-1936.165361 – ident: e_1_2_11_4_1 doi: 10.1111/eos.12775 – ident: e_1_2_11_50_1 doi: 10.1093/jjco/hyq030 – ident: e_1_2_11_42_1 doi: 10.1093/carcin/bgaa062 – ident: e_1_2_11_5_1 doi: 10.1186/s13046‐019‐1238‐4 – volume: 12 start-page: 176 issue: 1 year: 2022 ident: e_1_2_11_23_1 article-title: The ADAM9/UBN2/AKR1C3 Axis Promotes Resistance to Androgen‐Deprivation in Prostate Cancer publication-title: American Journal of Cancer Research – ident: e_1_2_11_26_1 doi: 10.1158/0008‐5472.CAN‐13‐2995 – ident: e_1_2_11_58_1 doi: 10.18632/oncotarget.20079 – ident: e_1_2_11_17_1 doi: 10.1016/j.oraloncology.2011.09.013 – ident: e_1_2_11_7_1 doi: 10.1038/srep16426 – ident: e_1_2_11_16_1 doi: 10.1615/CritRevTherDrugCarrierSyst.2016016272 – ident: e_1_2_11_32_1 doi: 10.1158/0008‐5472.CAN‐04‐4449 – ident: e_1_2_11_13_1 doi: 10.1186/1471‐2407‐8‐179 – ident: e_1_2_11_33_1 doi: 10.3390/cells5020016 – ident: e_1_2_11_49_1 doi: 10.3892/ol.2017.7284 – ident: e_1_2_11_36_1 doi: 10.1016/s1368‐8375(00)00021‐x – ident: e_1_2_11_60_1 doi: 10.1007/s12032‐025‐02645‐0 – ident: e_1_2_11_11_1 doi: 10.3390/ijms17091276 – ident: e_1_2_11_48_1 doi: 10.1038/s41368‐023‐00249‐w – ident: e_1_2_11_12_1 doi: 10.1016/j.eururo.2007.11.034 – ident: e_1_2_11_30_1 doi: 10.1158/1078‐0432.CCR‐14‐1740 – ident: e_1_2_11_52_1 doi: 10.1371/journal.pone.0054705 – ident: e_1_2_11_53_1 doi: 10.1016/j.oraloncology.2008.06.002 – ident: e_1_2_11_15_1 doi: 10.3892/or.2016.5259 – ident: e_1_2_11_38_1 doi: 10.1159/000324314 – ident: e_1_2_11_56_1 doi: 10.1111/odi.15076 – ident: e_1_2_11_54_1 doi: 10.1007/s12672‐024‐01422‐1 – ident: e_1_2_11_61_1 doi: 10.3389/fmed.2020.00214 – ident: e_1_2_11_27_1 doi: 10.7150/ijms.74751 – ident: e_1_2_11_35_1 doi: 10.4049/jimmunol.1303370 – ident: e_1_2_11_51_1 doi: 10.1158/0008‐5472.CAN‐16‐2609 – volume: 18 start-page: 7 issue: 1 year: 2015 ident: e_1_2_11_19_1 article-title: An Overview of Detection and Screening of Oral Cancer in Taiwan publication-title: Chinese Journal of Dental Research – ident: e_1_2_11_22_1 doi: 10.1155/2017/5815493 – ident: e_1_2_11_25_1 doi: 10.1371/journal.pone.0021816 – ident: e_1_2_11_41_1 doi: 10.1158/1078‐0432.CCR‐09‐2525 – volume: 94 start-page: 64 issue: 2 year: 2012 ident: e_1_2_11_34_1 article-title: Oral Cancer: Enduring Characteristics and Emerging Trends publication-title: Journal of the Michigan Dental Association – ident: e_1_2_11_8_1 doi: 10.1111/j.1834‐7819.2011.01349.x – volume: 10 start-page: 3828 issue: 11 year: 2020 ident: e_1_2_11_29_1 article-title: Resveratrol‐Mediated ADAM9 Degradation Decreases Cancer Progression and Provides Synergistic Effects in Combination With Chemotherapy publication-title: American Journal of Cancer Research – ident: e_1_2_11_20_1 doi: 10.1158/1535‐7163.MCT‐13‐1001 – ident: e_1_2_11_44_1 doi: 10.7150/thno.18551 – ident: e_1_2_11_28_1 doi: 10.3390/diagnostics10020122 – ident: e_1_2_11_39_1 doi: 10.2147/CMAR.S277096 – ident: e_1_2_11_47_1 doi: 10.1186/s13046‐019‐1455‐x – ident: e_1_2_11_9_1 doi: 10.1016/j.canlet.2018.02.010 – ident: e_1_2_11_40_1 doi: 10.1002/ijc.23974 – ident: e_1_2_11_57_1 doi: 10.1016/j.oraloncology.2020.104915 – ident: e_1_2_11_21_1 doi: 10.1074/jbc.M111.321190 – ident: e_1_2_11_14_1 doi: 10.1158/0008‐5472.CAN‐09‐4231 – ident: e_1_2_11_3_1 doi: 10.3322/caac.21492 – ident: e_1_2_11_24_1 doi: 10.3109/08941939.2012.728682 – ident: e_1_2_11_43_1 doi: 10.1111/jpi.12370 – ident: e_1_2_11_46_1 doi: 10.1016/j.oraloncology.2020.104798 – ident: e_1_2_11_6_1 doi: 10.1007/s11010‐009‐0217‐z – ident: e_1_2_11_37_1 doi: 10.1016/j.oraloncology.2008.05.017 – ident: e_1_2_11_55_1 doi: 10.1016/j.oraloncology.2017.12.005 – ident: e_1_2_11_62_1 doi: 10.1074/jbc.M701658200 |
| SSID | ssj0017932 |
| Score | 2.4225533 |
| SecondaryResourceType | online_first |
| Snippet | Oral cancer has a high incidence in Taiwan, and identifying prognostic biomarkers is crucial. This study investigated the role of a disintegrin and... |
| SourceID | proquest pubmed crossref |
| SourceType | Aggregation Database Index Database |
| Title | Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40523161 https://www.proquest.com/docview/3219324477 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBVtCmkuoU2_Nv1ALb0VhbUsWdZx600JodtC2TS5GdmSuj7EDsmaQn59NLZkJyULbS9mkW0Z5pnZN-N5Mwh9FCl3wQ702OdUECYUJYVONEkTLlWho0hPQeC8-JYcnbDjM342Dobs1CXr4qC8vldX8j-oujWHK6hk_wHZYVO34H47fN3RIeyOf4VxFmSNPx2b1gP5m81nCwkDZBToAKCSDrqyfq6ac6jFgfrzT99Bl58B4pe36Wm37L_ZDGT7a-vLYH6RU1MNKZlV1WdkTEWy1Sgoy1ZtSEGvmt9kMd6x7PY5VTU5bv3_pU83UA5lUZFvVt27yAQSEGkvV97ggBtdHYArjW9f42x3cd4hwSAXHfVN2P_odh1OPUSPqCP-MJNi_mNoCAbehPr-UFCPNTxnB22HO-8SjA1RQ8celk_Qrqf9eNZj-BQ9MPUeejyHUi2YtreHthe-yOEZOgyw4hFW3FjcwYrVFVZ4hBUPsOKqxoAf7mF9jk6-HC6zI-KnXZCSMrEmkpvCxW5Sa26n0ggTlVMjJI1UzJUsrU5lEcdJZKxgJrHSchVbyZW1MUu1pfELtFU3tXmFMGzIo5KWQjGmUqaKqbKacUuVi4e5mqAPwUT5Rd_UJA_BoDNp3pl0gt4H4-XO5cB3JFWbpr3KYwqsnzEhJuhlb9Vhm4DC_sYzr9HO-F69QVvry9a8dcRuXbzrsL4BF2JJHw |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Validation+of+ADAM9+as+a+Prognostic+Biomarker+in+Oral+Cancer&rft.jtitle=Oral+diseases&rft.au=Lu%2C+Jeng-Wei&rft.au=Shih%2C+Pei-Chen&rft.au=Chuang%2C+Show-Mei&rft.au=Tu%2C+Wan-Jung&rft.date=2025-06-16&rft.eissn=1601-0825&rft_id=info:doi/10.1111%2Fodi.15383&rft_id=info%3Apmid%2F40523161&rft.externalDocID=40523161 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1354-523X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1354-523X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1354-523X&client=summon |